share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alyeska Investment Group, L.P.(0.0%),Alyeska Fund GP, LLC(0.0%), etc.

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alyeska Investment Group, L.P.(0.0%),Alyeska Fund GP, LLC(0.0%), etc.

bluebird bio | SC 13G/A：超過5%持股股東披露文件(修正)-Alyeska Investment Group, L.P.(0.0%),Alyeska Fund GP, LLC(0.0%)等
美股SEC公告 ·  2024/11/15 05:45

Moomoo AI 已提取核心訊息

Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating that they no longer beneficially own more than five percent of bluebird bio, Inc.'s common stock. The filing, dated September 30, 2024, shows that each reporting person now owns 0% of the company's common stock, effectively ceasing their status as major shareholders. The addresses for all reporting persons are listed as 77 West Wacker Drive, 7th Floor, Chicago, IL 60601. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Alyeska Investment Group and Alyeska Fund GP, LLC classified as investment advisers and parent holding companies or control persons. The certification signed by Jason Bragg, Chief Financial Officer for both Alyeska entities, and Anand Parekh individually, asserts that the shares were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of bluebird bio, Inc.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating that they no longer beneficially own more than five percent of bluebird bio, Inc.'s common stock. The filing, dated September 30, 2024, shows that each reporting person now owns 0% of the company's common stock, effectively ceasing their status as major shareholders. The addresses for all reporting persons are listed as 77 West Wacker Drive, 7th Floor, Chicago, IL 60601. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Alyeska Investment Group and Alyeska Fund GP, LLC classified as investment advisers and parent holding companies or control persons. The certification signed by Jason Bragg, Chief Financial Officer for both Alyeska entities, and Anand Parekh individually, asserts that the shares were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of bluebird bio, Inc.
Alyeska投資集團(臨時代碼)、Alyeska基金GP有限責任公司以及Anand Parekh已向美國證券交易委員會提交了一份修訂後的13G/A表格，表明他們不再持有bluebird bio, Inc.普通股超過五個百分點的有利權益。該提交日期爲2024年9月30日，顯示每位報告人現在均不再擁有該公司普通股的持股比例，有效地終止了他們作爲主要股東的身份。所有報告人的地址都列在伊利諾伊州芝加哥的Wacker Drive西77號，7樓，郵編60601。根據1934年證券交易法案第13d-1(b)規定提交了申報，Alyeska投資集團和Alyeska基金GP有限責任公司都被分類爲投資顧問和母公司控股公司。由Alyeska實體的首席財務官Jason Bragg和Anand Parekh個人簽署的證明書聲明這些股份是以正常業務方式收購併持有，並非出於改變或影響bluebird bio, Inc.控制權的目的。
Alyeska投資集團(臨時代碼)、Alyeska基金GP有限責任公司以及Anand Parekh已向美國證券交易委員會提交了一份修訂後的13G/A表格，表明他們不再持有bluebird bio, Inc.普通股超過五個百分點的有利權益。該提交日期爲2024年9月30日，顯示每位報告人現在均不再擁有該公司普通股的持股比例，有效地終止了他們作爲主要股東的身份。所有報告人的地址都列在伊利諾伊州芝加哥的Wacker Drive西77號，7樓，郵編60601。根據1934年證券交易法案第13d-1(b)規定提交了申報，Alyeska投資集團和Alyeska基金GP有限責任公司都被分類爲投資顧問和母公司控股公司。由Alyeska實體的首席財務官Jason Bragg和Anand Parekh個人簽署的證明書聲明這些股份是以正常業務方式收購併持有，並非出於改變或影響bluebird bio, Inc.控制權的目的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Passage BIO
    PASG
    -- 0.830
    MiNK Therapeutics
    INKT
    -- 1.010
    Klotho Neurosciences
    KLTO
    -- 0.700
    Revelation Biosciences
    REVB
    -- 0.6570
    居里
    CRIS
    -- 4.2400

    解鎖榜首股票